BioCentury on BioBusiness,
Table: Top biotech products
Back to the parent article
Monday, January 7, 2013
At least 39 drugs developed and marketed by biotech
companies are anticipated to have more than $500 million in sales in 2012. This
compares to at least 35 in 2011. While Adderall XR dextroamphetamine/amphetamin
from Shire plc (LSE:SHP; NASDAQ:SHPG) is no longer expected to post
sales above $500 million, five new drugs have entered the list this year:
Angiomax bivalirudin from The Medicines Co. (NASDAQ:MDCO); Cimzia
ertolizumab pegol from UCB Group (Euronext:UCB); Eylea aflibercept from Regeneron
Pharmaceuticals Inc. (NASDAQ:REGN); Prolia/Xgeva denosumab from Amgen
Inc. (NASDAQ:AMGN); and Replagal agalsidase alfa from Shire plc (LSE:SHP;
Product sales as reported by companies listed below,
unless otherwise noted. Included are drugs developed by biotechs that were
acquired - Amylin Pharmaceuticals LLC; Cephalon Inc.; Genentech Inc.; Genzyme
Corp.; MedImmune LLC; and OSI Pharmaceuticals LLC - but
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2013 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
If you are a current subscriber, log in below or in the upper right corner of this
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial 4 Weeks of Access
Get a 4-week free trial subscription to see the important articles you are missing.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]